Market Closed -
Nyse
04:00:02 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
157.8
USD
|
+0.86%
|
|
-0.63%
|
-22.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,737
|
5,066
|
6,294
|
7,277
|
6,006
|
4,688
|
-
|
-
|
Enterprise Value (EV)
1 |
1,737
|
4,857
|
6,105
|
6,826
|
5,546
|
4,248
|
4,145
|
3,987
|
P/E ratio
|
-53
x
|
-85.9
x
|
-149
x
|
-157
x
|
-283
x
|
960
x
|
182
x
|
66.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
21.2
x
|
43.9
x
|
27
x
|
17.8
x
|
9.61
x
|
5.95
x
|
4.93
x
|
4.11
x
|
EV / Revenue
|
21.2
x
|
42.1
x
|
26.2
x
|
16.7
x
|
8.88
x
|
5.39
x
|
4.36
x
|
3.5
x
|
EV / EBITDA
|
-61.6
x
|
-114
x
|
-158
x
|
1,095
x
|
123
x
|
46.6
x
|
29
x
|
23
x
|
EV / FCF
|
-48.8
x
|
-87.5
x
|
-246
x
|
2,760
x
|
5,416
x
|
45.6
x
|
43.4
x
|
29.6
x
|
FCF Yield
|
-2.05%
|
-1.14%
|
-0.41%
|
0.04%
|
0.02%
|
2.2%
|
2.3%
|
3.37%
|
Price to Book
|
12.8
x
|
21.3
x
|
27.4
x
|
-
|
10.5
x
|
5.79
x
|
4.92
x
|
4.02
x
|
Nbr of stocks (in thousands)
|
23,402
|
26,935
|
27,358
|
28,892
|
29,524
|
29,711
|
-
|
-
|
Reference price
2 |
74.21
|
188.1
|
230.1
|
251.9
|
203.4
|
157.8
|
157.8
|
157.8
|
Announcement Date
|
2/25/20
|
2/23/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.05
|
115.4
|
233.4
|
407.9
|
624.8
|
788
|
951
|
1,140
|
EBITDA
1 |
-28.2
|
-42.55
|
-38.63
|
6.236
|
45.04
|
91.2
|
142.7
|
173.1
|
EBIT
1 |
-34.9
|
-56.21
|
-39.85
|
-47.59
|
-40.27
|
-14.74
|
13.12
|
71.18
|
Operating Margin
|
-42.53%
|
-48.72%
|
-17.07%
|
-11.67%
|
-6.45%
|
-1.87%
|
1.38%
|
6.24%
|
Earnings before Tax (EBT)
1 |
-33.2
|
-57.09
|
-41.97
|
-44.27
|
-19.91
|
7.815
|
33.43
|
100.5
|
Net income
1 |
-33.24
|
-57.2
|
-42.04
|
-44.88
|
-21.15
|
5.108
|
28.24
|
81.54
|
Net margin
|
-40.52%
|
-49.58%
|
-18.01%
|
-11%
|
-3.39%
|
0.65%
|
2.97%
|
7.15%
|
EPS
2 |
-1.400
|
-2.190
|
-1.540
|
-1.600
|
-0.7200
|
0.1644
|
0.8663
|
2.371
|
Free Cash Flow
1 |
-35.58
|
-55.5
|
-24.79
|
2.473
|
1.024
|
93.25
|
95.42
|
134.5
|
FCF margin
|
-43.37%
|
-48.1%
|
-10.62%
|
0.61%
|
0.16%
|
11.83%
|
10.03%
|
11.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
39.66%
|
2.27%
|
102.24%
|
66.86%
|
77.68%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
1,825.58%
|
337.86%
|
164.91%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/23/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
78.4
|
69.38
|
91.39
|
109.2
|
137.9
|
127.9
|
151.1
|
153.3
|
192.5
|
164
|
186
|
197.5
|
240.5
|
202.3
|
228.3
|
EBITDA
1 |
-1.477
|
-15.7
|
-0.931
|
-2.092
|
15.24
|
-0.68
|
5.627
|
1.895
|
32.96
|
11.94
|
15.12
|
21.17
|
43.04
|
15.3
|
23.55
|
EBIT
1 |
-1.821
|
-16.06
|
-14.01
|
-17.19
|
-0.335
|
-19.5
|
-16.6
|
-13.47
|
9.297
|
-15.22
|
-9.948
|
-4.853
|
15.55
|
-10.93
|
-0.5627
|
Operating Margin
|
-2.32%
|
-23.14%
|
-15.33%
|
-15.75%
|
-0.24%
|
-15.25%
|
-10.99%
|
-8.79%
|
4.83%
|
-9.28%
|
-5.35%
|
-2.46%
|
6.47%
|
-5.4%
|
-0.25%
|
Earnings before Tax (EBT)
1 |
-2.371
|
-16.59
|
-14.35
|
-16.6
|
3.275
|
-15.21
|
-11.74
|
-8.2
|
15.24
|
-9.355
|
-4.46
|
0.9106
|
20.82
|
-4.529
|
5.562
|
Net income
1 |
-2.391
|
-16.69
|
-14.49
|
-16.85
|
3.15
|
-15.42
|
-11.95
|
-8.54
|
14.76
|
-10
|
-4.263
|
0.4626
|
18.93
|
-7.071
|
4.354
|
Net margin
|
-3.05%
|
-24.06%
|
-15.86%
|
-15.43%
|
2.28%
|
-12.06%
|
-7.91%
|
-5.57%
|
7.67%
|
-6.1%
|
-2.29%
|
0.23%
|
7.87%
|
-3.5%
|
1.91%
|
EPS
2 |
-0.0900
|
-0.6100
|
-0.5300
|
-0.6000
|
0.1000
|
-0.5300
|
-0.4100
|
-0.2900
|
0.4900
|
-0.3400
|
-0.1522
|
0.003210
|
0.6349
|
-0.2394
|
0.0922
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/8/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/7/23
|
5/2/23
|
8/1/23
|
11/7/23
|
2/6/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
210
|
189
|
451
|
460
|
440
|
543
|
702
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-35.6
|
-55.5
|
-24.8
|
2.47
|
1.02
|
93.3
|
95.4
|
134
|
ROE (net income / shareholders' equity)
|
-21.9%
|
-31%
|
-18.3%
|
-12.4%
|
-3.96%
|
0.77%
|
3.08%
|
6.38%
|
ROA (Net income/ Total Assets)
|
-
|
-24.7%
|
-14.6%
|
-10.4%
|
-3.41%
|
0.6%
|
1.9%
|
3.6%
|
Assets
1 |
-
|
231.2
|
288.1
|
430
|
620.9
|
851.3
|
1,487
|
2,265
|
Book Value Per Share
2 |
5.800
|
8.810
|
8.400
|
-
|
19.40
|
27.30
|
32.10
|
39.20
|
Cash Flow per Share
2 |
-1.380
|
-2.030
|
-
|
0.4100
|
0.8400
|
2.570
|
3.820
|
-
|
Capex
1 |
2.74
|
2.46
|
4.67
|
9.1
|
23.6
|
24
|
28.8
|
39.1
|
Capex / Sales
|
3.34%
|
2.13%
|
2%
|
2.23%
|
3.78%
|
3.04%
|
3.02%
|
3.43%
|
Announcement Date
|
2/25/20
|
2/23/21
|
2/8/22
|
2/7/23
|
2/6/24
|
-
|
-
|
-
|
Last Close Price
157.8
USD Average target price
248.1
USD Spread / Average Target +57.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.44% | 4.69B | | +16.65% | 133B | | -4.05% | 11.52B | | -4.86% | 8.3B | | +7.79% | 3.42B | | -17.26% | 2.54B | | -13.36% | 2.03B | | -16.39% | 1.86B | | -31.24% | 1.59B | | -9.88% | 1.17B |
Medical Devices & Implants
|